Your browser doesn't support javascript.
loading
Antibiotic-Resistant Septicemia in Pediatric Oncology Patients Associated with Post-Therapeutic Neutropenic Fever.
Vázquez-López, Rosalino; Rivero Rojas, Omar; Ibarra Moreno, Andrea; Urrutia Favila, José Erik; Peña Barreto, Adan; Ortega Ortuño, Guadalupe Lizeth; Abello Vaamonde, Jorge Andrés; Aguilar Velazco, Ivanka Alejandra; Félix Castro, José Marcos; Solano-Gálvez, Sandra Georgina; Barrientos Fortes, Tomás; González-Barrios, Juan Antonio.
Affiliation
  • Vázquez-López R; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico. rosalino.vazquez@anahuac.mx.
  • Rivero Rojas O; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Ibarra Moreno A; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Urrutia Favila JE; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Peña Barreto A; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Ortega Ortuño GL; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Abello Vaamonde JA; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Aguilar Velazco IA; Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Félix Castro JM; Coordinación Ciclos Clínicos, Facultad de Ciencias de la Salud, Universidad Anáhuac México Campus Norte, Cuidad de México 52786, Mexico.
  • Solano-Gálvez SG; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
  • Barrientos Fortes T; Director Facultad de Ciencias de la Salud, Universidad Anáhuac México, Cuidad de México 52786, Mexico.
  • González-Barrios JA; Laboratorio de Medicina Genómica, Hospital Regional "Primero de Octubre", ISSSTE, Av. Instituto Politécnico Nacional 1669, Lindavista, Gustavo A. Madero, Ciudad de Mexico 07300, Mexico.
Antibiotics (Basel) ; 8(3)2019 Jul 30.
Article in En | MEDLINE | ID: mdl-31366110
Death in cancer patients can be caused by the progression of tumors, their malignity, or other associated conditions such as sepsis, which is a multiphasic host response to a pathogen that can be significantly amplified by endogenous factors. Its incidence is continuously rising, which reflects the increasing number of sick patients at a higher risk of infection, especially those that are elderly, pediatric, or immunosuppressed. Sepsis appears to be directly associated with oncological treatment and fatal septic shock. Patients with a cancer diagnosis face a much higher risk of infections after being immunosuppressed by chemotherapy, radiotherapy, or anti-inflammatory therapy, especially caused by non-pathogenic, Gram-negative, and multidrug-resistant pathogens. There is a notorious difference between the incidence and mortality rates related to sepsis in pediatric oncologic patients between developed and developing countries: they are much higher in developing countries, where investment for diagnosis and treatment resources, infrastructure, medical specialists, cancer-related control programs, and post-therapeutic care is insufficient. This situation not only limits but also reduces the life expectancy of treated pediatric oncologic patients, and demands higher costs from the healthcare systems. Therefore, efforts must aim to limit the progression of sepsis conditions, applying the most recommended therapeutic regimens as soon as the initial risk factors are clinically evident-or even before they are, as when taking advantage of machine learning prediction systems to analyze data.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Antibiotics (Basel) Year: 2019 Document type: Article Affiliation country: México Country of publication: Suiza

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Antibiotics (Basel) Year: 2019 Document type: Article Affiliation country: México Country of publication: Suiza